B
275.28
-7.44 (-2.63%)
| Penutupan Terdahulu | 282.72 |
| Buka | 282.43 |
| Jumlah Dagangan | 220,667 |
| Purata Dagangan (3B) | 271,328 |
| Modal Pasaran | 31,617,419,264 |
| Harga / Pendapatan (P/E TTM) | 111.00 |
| Harga / Pendapatan (P/E Ke hadapan) | 50.00 |
| Harga / Jualan (P/S) | 6.15 |
| Harga / Buku (P/B) | 7.37 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2026 |
| Margin Keuntungan | -9.40% |
| Margin Operasi (TTM) | 0.99% |
| EPS Cair (TTM) | -3.69 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 48.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 28.49% |
| Nisbah Semasa (MRQ) | 1.96 |
| Aliran Tunai Operasi (OCF TTM) | 212.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -120.68 M |
| Pulangan Atas Aset (ROA TTM) | -3.22% |
| Pulangan Atas Ekuiti (ROE TTM) | -11.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | BeOne Medicines Ltd. | Menaik | Menaik |
AISkor Stockmoo
0.4
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.40 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 17.31% |
| % Dimiliki oleh Institusi | 43.94% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Capital International, Inc./Ca/ | 31 Dec 2025 | 307,660 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 425.00 (RBC Capital, 54.39%) | Beli |
| Median | 411.00 (49.30%) | |
| Rendah | 405.00 (Barclays, 47.12%) | Beli |
| Purata | 413.00 (50.03%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 316.99 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 27 Feb 2026 | 405.00 (47.12%) | Beli | 316.99 |
| 04 Feb 2026 | 394.00 (43.13%) | Beli | 352.00 | |
| Guggenheim | 27 Feb 2026 | 410.00 (48.94%) | Beli | 316.99 |
| RBC Capital | 27 Feb 2026 | 425.00 (54.39%) | Beli | 316.99 |
| Truist Securities | 27 Feb 2026 | 412.00 (49.67%) | Beli | 316.99 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LEE CHAN HENRY | - | 298.91 | -341 | -101,928 |
| Jumlah Keseluruhan Kuantiti Bersih | -341 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -101,928 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 298.91 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LEE CHAN HENRY | Pegawai | 11 Mar 2026 | Jual automatik (-) | 341 | 298.91 | 101,928 |
| LEE CHAN HENRY | Pegawai | 11 Mar 2026 | Pelaksanaan pilihan | 341 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jan 2026 | Pengumuman | BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference |
| 06 Jan 2026 | Pengumuman | ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA |
| 23 Dec 2025 | Pengumuman | BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |